You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models

Authors

  • Jian Ye Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Nicholas W Gavras Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • David C Keeley Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Angela L Hughson Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Gary Hannon Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Tara G Vrooman Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Maggie L Lesch Department of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Carl J Johnston Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USADepartment of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Edith M Lord Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Brian A Belt Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • David C Linehan Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Jim Eyles Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK PubMed articlesGoogle scholar articles
  • Scott A Gerber Center for Tumor Immunology Research, University of Rochester Medical Center, Rochester, New York, USADepartment of Surgery, University of Rochester Medical Center, Rochester, New York, USADepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles

Citation

Ye J, Gavras NW, Keeley DC, et al
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
Journal for ImmunoTherapy of Cancer 2023;11:e006842. doi: 10.1136/jitc-2023-006842
Online issue publication 
May 04, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.